Last updated: July 1, 2026
Celgene v. Mylan (No. 21-1154): Litigation Summary, Claims at Issue, and Generic-Entry Implications
Celgene Corporation’s appeal in Celgene Corp. v. Mylan Pharms. Inc., No. 21-1154 (Fed. Cir.) concerns an asserted patent estate tied to lenalidomide (Revlimid). The case is part of the Paragraph IV framework that typically drives generic risk for immunomodulatory drugs with complex Orange Book protections.
Actionable conclusion: The docket posture and the Federal Circuit forum indicate the dispute is centered on claim construction and infringement/validity outcomes that can directly affect whether competing applicants can launch generic lenalidomide on entry timelines set by Hatch-Waxman Orange Book listings.
What is Celgene v. Mylan 21-1154 about?
Featured snippet answer: No. 21-1154 is a Federal Circuit appeal in a Hatch-Waxman-style patent dispute between Celgene and Mylan regarding Orange Book-listed patent rights for lenalidomide.
Which parties and forum govern the dispute
- Appellant/Plaintiff: Celgene Corporation
- Appellee/Defendant: Mylan Pharmaceuticals Inc.
- Court: United States Court of Appeals for the Federal Circuit
- Docket: 21-1154
Core dispute type
The case aligns with the standard structure of Paragraph IV litigation:
- Celgene asserts infringement of one or more Orange Book-listed patents.
- Mylan challenges the asserted patents on grounds such as non-infringement, invalidity, or both.
- The Federal Circuit appeal focuses on legal errors tied to claim scope, infringement standards, or validity determinations.
What patents were asserted in Celgene v. Mylan 21-1154?
Featured snippet answer: The docket number alone does not identify the specific patent numbers in a way that can be stated accurately here.
Why the specific patent list matters for outcome
In this litigation category, the claim scope, priority dates, and prosecution history are decisive. For business impact, investors and licensing teams need:
- the asserted patent family (composition, method-of-use, formulation, or manufacturing),
- which claims survived summary judgment,
- and whether invalidation or non-infringement drove the judgment appealed to the Federal Circuit.
How that feeds generic-launch timelines
For lenalidomide, even one surviving patent or remaining claim can block launch; conversely, a narrowing claim construction can make a design-around feasible.
What is the litigation timeline for No. 21-1154?
Featured snippet answer: Without the docket’s event-level entries (district court judgment date, notice of appeal date, panel decision date, mandate date), a complete and accurate timeline cannot be produced.
What the timeline typically contains in Federal Circuit Hatch-Waxman appeals
- District court: claim construction, summary judgment or trial outcomes.
- Federal Circuit: briefing on issues, panel decision, possible remand.
- Regulatory impact: consequences for whether FDA can allow approval and timing of market entry.
How strong is Celgene’s patent estate versus Mylan’s generic risk in this appeal?
Featured snippet answer: Litigation strength in this case is driven by the lower court record and Federal Circuit rulings on claim interpretation and invalidity.
Patent strength indicators used by appellate panels
For Hatch-Waxman appeals, the practical “strength” questions are:
- Did the district court’s claim construction align with intrinsic evidence?
- Were legal standards correctly applied to infringement?
- Did the invalidity analysis properly address anticipation/obviousness and motivation to combine?
- Were expert opinions properly tied to claim elements?
Commercial exposure typically tied to Federal Circuit outcomes
For lenalidomide generics, the commercial exposure is high because:
- multiple patents can be listed for a single reference product,
- settlements often depend on specific claim survival,
- and timing of potential entry often tracks the Patent-by-Patent status rather than a single “blocker” expiration.
What is the Orange Book status relevant to Celgene v. Mylan 21-1154?
Featured snippet answer: Orange Book status determines which patents must be addressed in the ANDA Paragraph IV notice that triggers litigation.
Why Orange Book listings control the business playbook
- If an ANDA applicant selects patents to “paragraph IV” but other unaddressed patents exist, FDA approval can still be blocked or delayed.
- If the litigated patents are narrowed or invalidated, the generic launch risk collapses.
How settlements usually map to Orange Book
Settlements in this space typically:
- specify launch dates tied to expiry or date-certain entry,
- allocate risk for non-settled patents,
- include “covenant not to sue” provisions within claim scope.
What generic entry risks exist if Celgene wins or loses on appeal?
Featured snippet answer: Federal Circuit outcomes directly translate into whether Mylan’s ANDA can reach approval and whether launch is blocked by surviving infringement findings.
If Celgene prevails on appeal
- The asserted patents remain enforceable as construed.
- Launch timing is pushed until expiry or until a remaining patent barrier is cleared via future design-around or additional litigation.
If Mylan prevails on appeal
- The remaining legal obstacles collapse if the court affirms non-infringement or invalidity.
- That can accelerate approval and market entry, subject to any other Orange Book-listed patents not resolved by this litigation.
Does this case involve Paragraph IV challenges or biosimilar-type risks?
Featured snippet answer: This is a Hatch-Waxman Paragraph IV drug patent dispute context. It is not a biosimilar pathway matter.
Why biosimilar standards do not apply
- Biosimilars use different statutory triggers (351(k)).
- The docket pattern here fits small-molecule ANDA litigation rather than biologics.
Which district court decision is under appeal in 21-1154?
Featured snippet answer: The district court decision and its date are required to accurately summarize the judgment, claim construction findings, and legal holdings, but those details are not available from the docket number alone in the current record.
What an appellate summary must capture for litigation analysis
A proper analysis includes:
- the asserted claims and elements,
- the lower court’s infringement and invalidity conclusions,
- standards of review on appeal (de novo vs clear error vs abuse of discretion),
- the Federal Circuit’s disposition (affirm, reverse, vacate, remand).
What is the practical impact on Mylan’s litigation posture and licensing strategy?
Featured snippet answer: The Federal Circuit decision changes expected value for Mylan’s ANDA path by altering the probability of a licensed launch date versus continued injunction exposure.
How pharma strategists use this kind of appeal
Decision-tree effect:
- Affirmance increases settlement leverage for brand against the generic.
- Reversal or invalidation increases generic launch probability and compresses settlement pricing for future agreements.
Portfolio-level implications for other generic applicants
If the Federal Circuit construes claims narrowly or invalidates key patent categories, it can:
- create momentum for design-arounds across the class,
- lower risk premiums for other ANDA filers.
Key Takeaways
- No. 21-1154 is a Federal Circuit appeal in a Hatch-Waxman patent dispute involving Celgene and Mylan in the lenalidomide competitive landscape.
- The business outcome depends on Federal Circuit legal holdings on claim scope and patent validity/enforcement, which can either sustain or remove barriers to generic entry.
- A complete, decision-grade litigation summary requires the district court judgment and the specific asserted patent numbers, because those define claim elements, expiration leverage, and injunction/entry triggers.
FAQs
- How do Federal Circuit standards of review affect outcomes in ANDA patent appeals like 21-1154?
- What role do claim construction outcomes play in determining infringement for complex small-molecule patents?
- How do surviving Orange Book patents after an appeal control FDA launch timing?
- What typical settlement terms emerge when a brand case is reversed on appeal in Hatch-Waxman litigation?
- How does an invalidation of one patent family affect design-around options for other ANDA filers?
References
- United States Court of Appeals for the Federal Circuit, Celgene Corp. v. Mylan Pharms. Inc., No. 21-1154.
